 |
|
Serial Changes of Cerebral Glucose Metabolism and Caudate Size in Persons at Risk for Huntington's Disease
Scott T. Grafton, MD;
John C. Mazziotta, MD, PhD;
Jorg J. Pahl, MD;
Peter St. George-Hyslop, MD;
Jonathan L. Haines, PhD;
James Gusella, PhD;
John M. Hoffman, MD;
Lewis R. Baxter, MD;
Michael E. Phelps, PhD
Arch Neurol. 1992;49(11):1161-1167.
Abstract
• Objective.
—To determine the rate of change of glucose metabolism and caudate size in persons at risk for Huntington's disease.
Design.
—Eighteen persons at risk for Huntington's disease had two positron emission tomographic glucose metabolic studies and two magnetic resonance imaging scans separated by 42 (±9) months.
Setting.
—Ambulatory research subjects at a teaching hospital with magnetic resonance imaging and positron emission tomographic technology.
Subjects.
—Seven of the individuals were Huntington' disease gene negative by testing at the polymorphic DNA loci D4S10, D4S43, and D4S125; the remainder were gene positive by genetic testing or onset of chorea after study entry.
Interventions.
—None.
Outcome Measures.
—Onset of chorea and imaging results.
Results.
—The gene-positive group demonstrated a significant 3.1 % loss of glucose metabolic rate per year in the caudate nucleus (95% confidence interval [CI], –4.64, –1.48) compared with the gene-negative group. There was a 3.6% per year increase in the magnetic resonance imaging bicaudate ratio (95% CI, 1.81, 5.37), a linear measure of caudate atrophy. The rate of change in caudate size did not correlate with the rate of change in caudate metabolism, suggesting that metabolic loss and atrophy may develop independently.
Conclusions.
—The results suggest that a reduction in caudate glucose metabolism and atrophy develop rapidly in Huntington's disease. The findings establish a strategy for using serial positron emission tomographic imaging to monitor experimental pharmacologic interventions in presymptomatic individuals who have developed caudate hypometabolism.
Author Affiliations
From the Division of Nuclear Medicine and Biophysics (Drs Mazziotta, Baxter, and Phelps), the Department of Neurology (Dr Mazziotta), the Department of Psychiatry (Dr Baxter), and the Laboratory of Nuclear Medicine (Department of Energy) of the UCLA School of Medicine, Los Angeles, Calif (Drs Mazziota, Baxter, and Phelps); The Molecular Neurogenetics Laboratory, Massachusetts General Hospital, Boston (Dr Haines and Gusella); the Department of Neurology, University of Southern California, Los Angeles (Dr Grafton); the Department of Psychiatry, University of Oklahoma, Oklahoma City (Dr Pahl); the Division of Nuclear Medicine, Duke University, Durham, NC (Dr Hoffman); and the Departments of Neurology and Medicine, University of Toronto (Ontario) (Dr St. George-Hyslop).
Footnotes
Accepted for publication July 20, 1992.
Reprint requests to Department of Neurology, University of Southern California School of Medicine, 1510 San Pablo Ave, Los Angeles, CA 90033-4606 (Dr Grafton).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Meclizine is neuroprotective in models of Huntington's disease
Gohil et al.
Hum Mol Genet 2011;20:294-300.
ABSTRACT
| FULL TEXT
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation
Chaturvedi et al.
Hum Mol Genet 2010;19:3190-3205.
ABSTRACT
| FULL TEXT
Impaired PGC-1{alpha} function in muscle in Huntington's disease
Chaturvedi et al.
Hum Mol Genet 2009;18:3048-3065.
ABSTRACT
| FULL TEXT
Polyglutamine diseases: emerging concepts in pathogenesis and therapy
Shao and Diamond
Hum Mol Genet 2007;16:R115-R123.
ABSTRACT
| FULL TEXT
Huntingtin-deficient zebrafish exhibit defects in iron utilization and development
Lumsden et al.
Hum Mol Genet 2007;16:1905-1920.
ABSTRACT
| FULL TEXT
Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study
Kipps et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:650-655.
ABSTRACT
| FULL TEXT
Onset and rate of striatal atrophy in preclinical Huntington disease
Aylward et al.
Neurology 2004;63:66-72.
ABSTRACT
| FULL TEXT
Striatal neural grafting improves cortical metabolism in Huntington's disease patients
Gaura et al.
Brain 2004;127:65-72.
ABSTRACT
| FULL TEXT
Expression of Full-length Polyglutamine-expanded Huntingtin Disrupts Growth Factor Receptor Signaling in Rat Pheochromocytoma (PC12) Cells
Song et al.
J. Biol. Chem. 2002;277:6703-6707.
ABSTRACT
| FULL TEXT
Clinical markers of early disease in persons near onset of Huntington's disease
Paulsen et al.
Neurology 2001;57:658-662.
ABSTRACT
| FULL TEXT
Huntington's disease progression: PET and clinical observations
Andrews et al.
Brain 1999;122:2353-2363.
ABSTRACT
| FULL TEXT
Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
Harris et al.
Brain 1999;122:1667-1678.
ABSTRACT
| FULL TEXT
Clinical correlation of striatal 1H MRS changes in Huntington's disease
Sanchez-Pernaute et al.
Neurology 1999;53:806-806.
ABSTRACT
| FULL TEXT
Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial
Kremer et al.
Neurology 1999;53:1000-1000.
ABSTRACT
| FULL TEXT
Motor Changes in Presymptomatic Huntington Disease Gene Carriers
Siemers et al.
Arch Neurol 1996;53:487-492.
ABSTRACT
Protein:Protein Interactions in Alzheimer's Disease and the CAG Triplet Repeat Diseases
Strittmatter et al.
Cold Spring Harb Symp Quant Biol 1996;61:597-605.
ABSTRACT
Longitudinal Neuropsychological and Genetic Linkage Analysis of Persons at Risk for Huntington's Disease
Giordani et al.
Arch Neurol 1995;52:59-64.
ABSTRACT
|
